UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 525

Sortiert nach

Mental Health Clinicians’ Screening and Intervention Practices to Reduce Suicide Risk in Autistic Adolescents and Adults

Journal of autism and developmental disorders, 2020-10, Vol.50 (10), p.3450-3461

2020

Volltextzugriff (PDF)

Factors Influencing the Use of Cognitive–Behavioral Therapy with Autistic Adults: A Survey of Community Mental Health Clinicians

Journal of autism and developmental disorders, 2019-11, Vol.49 (11), p.4421-4428

2019

Volltextzugriff (PDF)

Concordance between a U.S. Educational Autism Classification and the Autism Diagnostic Observation Schedule

Journal of clinical child and adolescent psychology, 2020-07, Vol.49 (4), p.469-475

2020

Volltextzugriff (PDF)

[88] VIRAL KINETICS DURING 14-DAY TREATMENT WITH DEBIO-025 DEMONSTRATE EFFICIENT BLOCKING OF VIRAL REPLICATION IN DIFFERENT HCV GENOTYPES WITHOUT SIGNS OF EMERGING VIRAL RESISTANCE

Journal of hepatology, 2007, Vol.46, p.S40-S40

2007

Volltextzugriff (PDF)

946 PK-PD MODELING OF VIRAL KINETICS DURING TREATMENT WITH DEBIO-025 PLUS PEGYLATED INTERFERON ALPHA-2A IN TREATMENT-NAIVE HCV PATIENTS

Journal of hepatology, 2009, Vol.50, p.S344-S344

2009

Volltextzugriff (PDF)

95 EFFICACY AND SAFETY OF THE CYCLOPHILIN INHIBITOR DEBIO 025 IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN IN PREVIOUSLY NULL-RESPONDER GENOTYPE 1 HCV PATIENTS

Journal of hepatology, 2009, Vol.50, p.S40-S40

2009

Volltextzugriff (PDF)

Biodegradation of a colloidal ester-based polyurethane by soil fungi

International biodeterioration & biodegradation, 1994, Vol.33 (2), p.103-113

1994

Volltextzugriff (PDF)

[787] THE REDUCTION OF BOTH CYCLOPHILIN B AND HCV-RNA BY THE CYCLOPHILIN INHIBITOR DEBIO-025 CONFIRMS THE IMPORTANCE OF CYCLOPHILIN B FOR HCV REPLICATION IN MAN

Journal of hepatology, 2007, Vol.46, p.S296-S296

2007

Volltextzugriff (PDF)

Submucosal lipoma of the large intestine masquerading as a colonic malignancy

Journal of surgical case reports, 2011-02, Vol.2011 (2), p.4-4

2011

Volltextzugriff (PDF)

Simple Numerical Method to Compute Viscous Lift Loss of Wings

Journal of aircraft, 1998-01, Vol.35 (1), p.27-32

Crabbe, R. S

1998

Volltextzugriff (PDF)

Scorecards for health system performance assessment: The New Zealand example

Health policy (Amsterdam), 2011-12, Vol.103 (2), p.200-208

2011

Volltextzugriff (PDF)

Analysis of the human KCNH2(HERG) gene: Identification and characterization of a novel mutation Y667X associated with long QT syndrome and a non-pathological 9 bp insertion

Human mutation, 2000-05, Vol.15 (5), p.483-483

2000

Volltextzugriff (PDF)

Recombinant human growth hormone for children born small for gestational age: Meta-analysis confirms the consistent dose-effect relationship on catch-up growth

Journal of endocrinological investigation, 2008-04, Vol.31 (4), p.346-351

2008

Volltextzugriff (PDF)

An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C

Expert opinion on investigational drugs, 2009-02, Vol.18 (2), p.211-220

2009

Volltextzugriff (PDF)

PHARMACOKINETICS OF PHVS719, EXTENDED-RELEASE TABLET FORMULATION OF PHA121, A FIRST-IN-CLASS ORAL HUMAN BRADYKININ B2-RECEPTOR ANTAGONIST

Annals of allergy, asthma, & immunology, 2022-11, Vol.129 (5), p.S32-S33

2022

Volltextzugriff (PDF)

DEVELOPMENT OF PHVS719: AN ORAL EXTENDED-RELEASE BRADYKININ B2 RECEPTOR ANTAGONIST TO PREVENT HEREDITARY ANGIOEDEMA ATTACKS

Annals of allergy, asthma, & immunology, 2022-11, Vol.129 (5), p.S31-S31

2022

Volltextzugriff (PDF)

Intermittent recombinant growth hormone treatment in short children born small for gestational age: four-year results of a randomized trial of two different treatment regimens

Hormone research, 2006-01, Vol.66 (3), p.118-123

2006

Volltextzugriff (PDF)

4 ONCE DAILY ALISPORIVIR (DEB025) PLUS PEGIFNALFA2A/RIBAVIRIN RESULTS IN SUPERIOR SUSTAINED VIROLOGIC RESPONSE (SVR24) IN CHRONIC HEPATITIS C GENOTYPE 1 TREATMENT NAIVE PATIENTS

Journal of hepatology, 2011-03, Vol.54, p.S2-S2

2011

Volltextzugriff (PDF)

Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage

The New England journal of medicine, 1983-03, Vol.308 (11), p.619

1983

Volltextzugriff (PDF)

755 SUSTAINED VIROLOGICAL RESPONSE AFTER 4-WEEK TREATMENT WITH DEBIO 025 MONOTHERAPY OR COADMINISTERED WITH PEG-IFNα2A IN HCV GENOTYPE 1 AND 3 PATIENTS

Journal of hepatology, 2010, Vol.52, p.S294-S294

2010

Volltextzugriff (PDF)

Arteriovenous fistula at the site of balloon dilatation complicating femoropopliteal angioplasty

Cardiovascular and interventional radiology, 1997-01, Vol.20 (1), p.54-56

1997

Volltextzugriff (PDF)

P152 PHA-022121, A SELECTIVE BRADYKININ-B2-RECEPTOR ANTAGONIST, IS SAFE AND SHOWS RAPID ORAL BIOAVAILABILITY IN HUMANS

Annals of allergy, asthma, & immunology, 2020-11, Vol.125 (5), p.S21-S22

2020

Volltextzugriff (PDF)

P151 BRADYKININ CHALLENGE PROVIDES SURROGATE ENDPOINTS FOR HEREDITARY ANGIOEDEMA TREATMENT USING BRADYKININ-B2-RECEPTOR ANTAGONISTS

Annals of allergy, asthma, & immunology, 2020-11, Vol.125 (5), p.S21-S21

2020

Volltextzugriff (PDF)

748 EFFICACY OF STANDARD OF CARE THERAPY FOLLOWING EXPERIMENTAL DEBIO 025 TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C

Journal of hepatology, 2010, Vol.52, p.S291-S291

2010

Volltextzugriff (PDF)

Pharmacokinetics of lubeluzole (Prosynap) after single intravenous doses in healthy subjects

International journal of clinical pharmacology and therapeutics, 1998-09, Vol.36 (9), p.490

1998

Volltextzugriff (PDF)

1 – 25 von 525

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(432)
Mit Volltextzugriff
(431)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(288)
Life Sciences & Biomedicine
(242)
Animals
(157)
Humans
(148)
Male
(126)
Biological And Medical Sciences
(112)
Mice
(106)
Female
(101)
Medical Sciences
(77)
Neurosciences
(56)
Pharmacology & Pharmacy
(54)
Neurosciences & Neurology
(51)
Ethanol
(42)
Adult
(39)
Fundamental And Applied Biological Sciences. Psychology
(37)
Toxicology
(37)
Mice, Inbred Strains
(35)
Ethanol - Pharmacology
(34)
Middle Aged
(30)
Substance Abuse
(30)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Mental Health Clinicians’ Screening and Intervention Practices to Reduce Suicide Risk in Autistic Adolescents and Adults

Factors Influencing the Use of Cognitive–Behavioral Therapy with Autistic Adults: A Survey of Community Mental Health Clinicians

Concordance between a U.S. Educational Autism Classification and the Autism Diagnostic Observation Schedule

[88] VIRAL KINETICS DURING 14-DAY TREATMENT WITH DEBIO-025 DEMONSTRATE EFFICIENT BLOCKING OF VIRAL REPLICATION IN DIFFERENT HCV GENOTYPES WITHOUT SIGNS OF EMERGING VIRAL RESISTANCE

946 PK-PD MODELING OF VIRAL KINETICS DURING TREATMENT WITH DEBIO-025 PLUS PEGYLATED INTERFERON ALPHA-2A IN TREATMENT-NAIVE HCV PATIENTS

95 EFFICACY AND SAFETY OF THE CYCLOPHILIN INHIBITOR DEBIO 025 IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN IN PREVIOUSLY NULL-RESPONDER GENOTYPE 1 HCV PATIENTS

Biodegradation of a colloidal ester-based polyurethane by soil fungi

[787] THE REDUCTION OF BOTH CYCLOPHILIN B AND HCV-RNA BY THE CYCLOPHILIN INHIBITOR DEBIO-025 CONFIRMS THE IMPORTANCE OF CYCLOPHILIN B FOR HCV REPLICATION IN MAN

Submucosal lipoma of the large intestine masquerading as a colonic malignancy

Simple Numerical Method to Compute Viscous Lift Loss of Wings

Scorecards for health system performance assessment: The New Zealand example

Analysis of the human KCNH2(HERG) gene: Identification and characterization of a novel mutation Y667X associated with long QT syndrome and a non-pathological 9 bp insertion

Recombinant human growth hormone for children born small for gestational age: Meta-analysis confirms the consistent dose-effect relationship on catch-up growth

An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C

PHARMACOKINETICS OF PHVS719, EXTENDED-RELEASE TABLET FORMULATION OF PHA121, A FIRST-IN-CLASS ORAL HUMAN BRADYKININ B2-RECEPTOR ANTAGONIST

DEVELOPMENT OF PHVS719: AN ORAL EXTENDED-RELEASE BRADYKININ B2 RECEPTOR ANTAGONIST TO PREVENT HEREDITARY ANGIOEDEMA ATTACKS

Intermittent recombinant growth hormone treatment in short children born small for gestational age: four-year results of a randomized trial of two different treatment regimens

4 ONCE DAILY ALISPORIVIR (DEB025) PLUS PEGIFNALFA2A/RIBAVIRIN RESULTS IN SUPERIOR SUSTAINED VIROLOGIC RESPONSE (SVR24) IN CHRONIC HEPATITIS C GENOTYPE 1 TREATMENT NAIVE PATIENTS

Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage

755 SUSTAINED VIROLOGICAL RESPONSE AFTER 4-WEEK TREATMENT WITH DEBIO 025 MONOTHERAPY OR COADMINISTERED WITH PEG-IFNα2A IN HCV GENOTYPE 1 AND 3 PATIENTS

Arteriovenous fistula at the site of balloon dilatation complicating femoropopliteal angioplasty

P152 PHA-022121, A SELECTIVE BRADYKININ-B2-RECEPTOR ANTAGONIST, IS SAFE AND SHOWS RAPID ORAL BIOAVAILABILITY IN HUMANS

P151 BRADYKININ CHALLENGE PROVIDES SURROGATE ENDPOINTS FOR HEREDITARY ANGIOEDEMA TREATMENT USING BRADYKININ-B2-RECEPTOR ANTAGONISTS

748 EFFICACY OF STANDARD OF CARE THERAPY FOLLOWING EXPERIMENTAL DEBIO 025 TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C

Pharmacokinetics of lubeluzole (Prosynap) after single intravenous doses in healthy subjects

Suchergebnisse filtern